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Phosphoinositide 3-kinase  (PI3K) plays a central role in inﬂammation, allergy, cardiovascular, and metabolic
disease. Obesity is accompanied by chronic, low-grade inﬂammation. As PI3K plays a major role in leukocyte
recruitment, targeting of PI3K has been considered to be a strategy for attenuating progression of obesity to insulin
resistance and type 2 diabetes. Indeed, PI3K null mice are protected from high fat diet–induced obesity, metabolic
inﬂammation, fatty liver, and insulin resistance. The lean phenotype of the PI3K-null mice has been linked to
increased thermogenesis and energy expenditure. Surprisingly, the increase in fat mass and metabolic aberrations
were not linked to PI3K activity in the hematopoietic compartment. Thermogenesis and oxygen consumption are
modulated by PI3K lipid kinase–dependent and –independent signaling mechanisms. PI3K signaling controls
metabolic and inﬂammatory stress, and may provide an entry point for therapeutic strategies in metabolic disease,
inﬂammation, and cardiovascular disease.
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Introduction
Phosphoinositide 3-kinases (PI3Ks) have been
shown to play key roles in the control of cel-
lular metabolism, cell growth, proliferation, sur-
vival, and migration. The deregulation of these
processes promotes chronic inﬂammation, tumor
progression, and metabolic deviations (for a re-
view, see Ref. 1). Class I PI3Ks produce the
lipid second messenger phosphoinositol(3,4,5)-
trisphosphate (PtdIns(3,4,5)P3), which serves as
a docking site for selected pleckstrin homol-
ogy (PH) domain–containing proteins, including
phosphoinositide-dependent kinase 1 (PDK1) and
protein kinase B (PKB/Akt). While class IA PI3Ks
are tightly associatedwith a p85-like regulatory sub-
unit (encoded by the PIK3R1, PIK3R2, and PIK3R3
gene loci) and are linked to protein tyrosine kinase
receptor activation, the only member of the class IB
PI3Ks, PI3K , forms a heterodimer with a p84 or
p101 adaptor protein. PI3K operates downstream
of G protein–coupled receptors (GPCRs)2,3 and is
activated by trimeric G protein G subunits. Both
the p84 and p101 adaptor proteins sensitize the cat-
alytic subunit of PI3K (p110) for G input,4
but the p110–p84 complex additionally requires
interactionwith the activated small G protein Ras to
be fully operational.5 The p110–p84 and p110–
p101 complexes can signal in a nonredundant fash-
ion, and can operate in distinct plasma membrane
micro-domains.3
PI3K promotes inﬂammation and
modulates cardiovascular parameters
It was demonstrated early on that PI3K attenu-
ates in vivo leukocytemigration toward chemokines:
neutrophil recruitment2 and dendric cell move-
ment6 are attenuated in mice lacking a functional
p110 subunit. Protection of 110 null animals was
shown to involve control of the replenishment of
inﬂammatory cells to inﬂammation sites in inﬂam-
matory and allergic disease models. This observa-
tion was also observed following selective PI3K
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Figure 1. Implications of PI3K signaling in metabolic disease, obesity, and cardiovascular disease. PI3K downstream signaling
attenuates adaptive thermogenesis via a kinase-independent and a lipid kinase–dependent pathway. Mice with functional PI3K
therefore accumulate more body fat when kept on a high fat diet. The onset of obesity promotes the development of metabolic
disease, resulting in dyslipidemia, metabolic inﬂammation, and insulin-resistant tissues. An obesity-dependent, persistent low-
grade inﬂammatory state contributes to macrophage recruitment to adipose tissue. Furthermore, PI3K drives macrophage
accumulation in the intima, and thus contributes to atherosclerotic plaque formation. Hypertension, linked to PI3K through the
action of angiotensin II, favors rupture of atherosclerotic plaques. Finally, thrombosis can lead to blockage of coronary arteries.
After a cardiac event, PI3K can support inﬂammatory processes worsening reperfusion injury. HSL: hormone sensitive lipase.
inhibition. It was subsequently demonstrated
that inhibition of PI3K alleviated symptoms in
rheumatoid arthritis7 and systemic lupus mouse
models,8 and that anaphylaxis was promoted by
mast cell activation and degranulation driven by
a PI3K-dependent autocrine/paracrine activation
loop.9
Furthermore, in PI3-null platelets, aggrega-
tion and thrombosis were reduced in response to
ADP. Loss of PI3K activity correlates with at-
tenuated(IIb)(3) ﬁbrinogen receptor activation-
and protects fromADP-induced platelet-dependent
thromboembolic vascular occlusion.10 While cells of
hematopoietic origin express high levels of p110
protein, PI3K also plays an important role in tis-
sues where it is less prominently expressed. For
example, in cardiomyocytes p110 is linked to
cardiac contractility, serving as a scaffold protein
for phosphodiesterase 3B (PDB3). Lack of p110
leads to increased basal and adrenergic receptor–
induced cAMP-protein kinase A (PKA) signaling
in cardiomyocytes, and this translates into in-
creased heart contractile force. Mice expressing a
catalytically inactive (KI) p110 (with Lys833 mu-
tated to Arg), mimicking pharmaceutical inhibi-
tion of the enzyme, show no increase in cAMP,
demonstrating that this pathway operates indepen-
dently of PI3K lipid kinase activity. Moreover,
p110KI/KI mice were protected in a model of cardiac
overload.11
In atherosclerosis, the role of inﬂammation has
attracted attention, as some steps in the action of
atherogenic lipoproteins and cytokines act through
PI3K. PI3K seems to promote early steps in the
generation of atherosclerotic lesions. In murine
models of atherosclerosis, such as the apolipopro-
tein E (ApoE)-null and low density lipopro-
tein receptor (LDLR)-null mice, either genetic
(ApoE−/− × p110−/− or LDLR−/− × p110−/−)
or pharmacological manipulation of PI3K activity
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counteracted plaque formation. Interestingly,
plaques forming in p110-null mice were stabi-
lized by the inclusion of increased levels of collagen,
which clinically correlates with a better prognosis.
Plaque formation was also linked to the hematopoi-
etic cell lineages, as the transplantation of p110−/−
bone marrow into a wild-type host recapitulated
the p110-null phenotype. Mechanistically, loss of
p110 decreases macrophage and T cell inﬁltration
into the intima.12,13 Once the atherosclerotic le-
sions progress tonarrowingof blood vessels through
stenosis, smooth muscle migration has been re-
ported to be potentiated by PI3K-dependent
signals.14
As atherosclerotic plaques are formed, high blood
pressure is a major risk factor for subsequent
plaque rupture, stenosis, and, ﬁnally, fatal throm-
botic events. In the development of hypertension,
the renin–angiotensin system plays a major role by
generating angiotensin II that elicits reactive oxygen
species (ROS) within endothelial cells via GPCR
stimulation. ROS production and the opening of
PI3K-dependent L-type Ca2+ channels, leading to
inﬂux of extracellular Ca2+, mediate smoothmuscle
contraction. Most importantly, mice lacking PI3K
are protected from angiotensin II–induced hyper-
tension, ROS production, and vascular damage.15
PI3K–insulin resistance, control of
thermogenesis, and obesity
Obesity is accompanied by chronic low-grade in-
ﬂammation (metabolic inﬂammation), which has
been proposed to be a cause of progressing insulin
resistance, leading to the initiation of type II di-
abetes in obese patients.16,17 It was also proposed
that metabolic inﬂammation affects energy balance
during the development of obesity.18 Indeed, clin-
ical studies suggest that speciﬁc anti-inﬂammatory
treatments can improve glucose homeostasis in di-
abetics. Along these lines, we and others have re-
cently found that loss of functional PI3K leads
to a major improvement of insulin sensitivity in
mice kept on a high fat diet. Obesity-dependent
macrophage inﬁltration into adipose tissue was at-
tenuated in p110-null animals, and macrophage
markers and inﬂammatory cytokine proﬁles were
reduced in white adipose tissue.19,20 One interest-
ing outcome of our study was the observation that
p110−/− mice on a high fat diet accumulated sub-
stantially less fat mass than wild-type mice, while
calorie intake and nonadipose tissuemass was unaf-
fected. The difference in body weight increase could
be linked to increased thermogenesis in p110-null
animals, triggered by lipid kinase–dependent and
–independent pathways. Moreover, the lean phe-
notype accompanying increased thermogenesis in
p110-null mice was independent from PI3K ac-
tivity within the hematopoietic compartment, since
the energy expenditure and oxygen consumption
was determined by the PI3K status of the host
and not by the genotype of the transplanted bone
marrow.20
The PI3K signaling signature reﬂects a role in
control ofmetabolic and inﬂammatory stress.As de-
scribed above and summarized in Figure 1, PI3K
inhibition might constitute the entry point for
strategies for therapeutic intervention in metabolic
and inﬂammatory disease. Additionally, multiple
connections to PI3K signaling involve processes
in atherosclerotic plaque formation, platelet aggre-
gation, hypertension, and others, providing novel
possibilities for cardioprotective therapies.
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